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Summary 
Two important questions on the molecular mechanism of the BCL2 proteins involve the 
interaction network between pro- and anti-apoptotic members and the role of their 
translocation to the mitochondrial membrane during apoptosis. By quantifying the 
molecular interactions of BID and tBID with BCLXLΔCt in solution and in membranes by 
fluorescence correlation spectroscopy, we found that: 1) only the active form tBID binds 
to BCLXLΔCt, and 2) the membrane strongly promotes binding between them. 
Particularly, a BH3 peptide from BID disrupts the tBID/BCLXL complex in solution, but 
only partially in lipid bilayers. These data indicate that tBID/BCLXL interactions in 
solution and lipid membranes are distinct, and support a model in which BCLXL 
inhibition of tBID takes place predominantly at the membrane. Our findings imply an 
active role of the membrane in modulating the interactions between BCL2 proteins that 
has been underestimated. 
Introduction  
The proteins of the BCL2 family are key regulators of apoptosis that control the 
permeability of the mitochondrial outer membrane to cytochrome c (cyt c) and other 
apoptotic factors. They have an important role in the formation of tumors and in cellular 
responses to anticancer treatments1-3. The members of the family are classified into three 
subgroups: i) antiapoptotic proteins, like BCL2 or BCLXL, that inhibit apoptosis by 
binding the proapoptotic members; ii) proapoptotic proteins like BAX or BAK, that are 
believed to participate directly in permeabilization of the mitochondrial outer membrane 
(MOM); and iii) BH3-only proteins, which are further classified as direct activators and 
sensitizers/derepressors.  Direct activators, like BID, activate BAX and BAK for MOM 
permeabilization4, while sensitizer/derepressor BH3-only proteins induce apoptosis by 
binding to and neutralizing anti-apoptotic Bcl-2 members5. Under normal conditions BID 
is inactive in the cytosol, but in the presence of apoptotic stimuli it is proteolytically 
cleaved to give an active truncated form called tBID that induces cyt c release6.  
Despite intense research, the molecular mechanisms of action of the proteins of the BCL2 
family remain controversial. At the center of the debate, two questions seem to be crucial. 
First, the translocation to the MOM that most members of the family experience during 
apoptosis activation. Second, the interactions between them, which determine the final 
outcome of whether or not apoptosis is induced. Three models have been proposed to 
explain how the BCL2 proteins regulate apoptosis7. The “indirect model” states that the 
antiapoptotic members are bound to intrinsically active BAX and BAK, thus blocking 
their action and ensuring cell survival. During apoptosis, the BH3-only proteins are 
stimulated and bind to the antiapoptotic proteins, thus liberating BAX and BAK to induce 
cyt c release8-10. The “direct activation model” states that BAX and BAK are normally 
inactive and during apoptosis they are activated by the BH3-only proteins to promote 
MOM permeabilization11, 12. In this scenario the antiapoptotic proteins block cell death by 
binding and neutralizing BH3-only proteins. Recent data support a third alternative, the 
“embedded together” model, which assumes that insertion into the MOM during 
apoptosis affects the affinities between the different BCL2 proteins and exposes new 
interaction surfaces4, 13. Since the role of the membrane has been underestimated for a 
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long time, there is a lack of experimental data for the interaction of these proteins in 
membranes and, as a result, their nature and relative importance remain unknown. 
To establish the importance of the MOM, it is essential to examine the strength of the 
interactions between BCL2 proteins in aqueous and lipid environments. For this purpose, 
a chemically defined system that avoids unwanted effects of unknown factors is required. 
Cell-free systems have been shown to reproduce satisfactorily the features of the BCL2 
proteins observed during apoptosis4, 14, 15. We performed a comparative and quantitative 
analysis of the nature and strength of the interactions between human BID or tBID and 
human BCLXLCt in aqueous solution and in the membrane using reconstituted systems. 
We used a new variant of fluorescence cross-correlation spectroscopy (FCCS) to 
demonstrate that active tBID, but not full length BID, binds to BCLXLCt in solution, and 
that such interaction is strongly enhanced in the membrane. This finding sheds light on a 
key event in MOM permeabilization that is the contribution of the membrane 
environment to the modulation of interactions between BCL2 members. Altogether, our 
data suggest that BCLXL neutralizes tBID mainly at the membrane and support a model in 
which membrane association represents an additional regulatory stage for the control of 
MOM permeabilization. 
Results 
tBID and BCLXLCt induce each other’s binding to membranes 
Because chemically defined systems are necessary to quantify the interactions between 
tBID and BCLXL under controlled conditions, we used a cell-free reconstituted system 
with highly purified proteins and model membranes. We selectively mutated recombinant 
tBID and BCLXLCt to allow fluorescent labeling at single cysteines with Alexa647 and 
Alexa488, respectively. The mutations introduced and the positions of labeling in the 
proteins are highlighted in their structures shown in Figures 1a and b. To ensure that our 
system mimics as faithfully as possible the natural process, we checked that the labeled 
proteins, namely tBIDred and BCLXLCtgreen, retained their ability to induce or inhibit cyt 
c release from isolated mitochondria at concentrations comparable to the unlabeled wild 
type versions (Fig. 1c,d).  
We investigated the membrane binding properties of tBIDred and BCLXLCtgreen in giant 
unilamellar vesicles (GUVs). These are model membrane systems that offer the 
advantage of free-standing bilayers with sizes ranging from a few to hundreds of 
micrometers, therefore being suitable for optical microscopy and fluorescence correlation 
spectroscopy (FCS). 
tBIDred did not bind to vesicles containing phosphatidylglycerol (Fig. 2a), but showed 
specific binding to GUVs containing cardiolipin (CL) (Fig. 2b), in accordance with 
previous reports on the lipid-mediated selectivity of tBID binding to lipid membranes16-
21. Interestingly, tBIDred associated to GUVs containing tethered BCLXLCt (see below), 
even in the absence of CL (Fig 2c) (see control without BCLXLCt in Supplementary 
Fig. 1).The active, cleaved form tBID was required for membrane binding. Full length 
BID labeled with Bodipy did not show binding to CL containing vesicles under similar 
conditions (Fig. 2d).  
Next we analyzed membrane binding of BCLXLCtgreen. At neutral pH, the protein 
remained in the aqueous phase (Fig. 2e), but bound to anionic vesicles at acidic pH (Fig. 
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2f)22. Moreover, we tethered BCLXLCtgreen to GUVs at neutral pH via its histidine tag 
when small amounts of the lipid derivative DOGS-NTA-Ni (Ni-lipid) were incorporated 
into GUVs (Fig. 2g). This non-covalent association with the lipid moiety mimics the 
membrane anchored state of full length BCLXL via its C-terminal transmembrane helix23. 
In addition, tBID induced BCLXLCtgreen association to CL containing GUVs at neutral 
pH (Fig 2h). This indicates that hydrophobic fragments of BCLXL besides the absent C-
terminus also participate in the tBID-induced membrane interaction. These results are in 
accordance with those that previously suggested a role for BCLXL helices 5 and 6 in the 
membrane binding process24. The fluorescence spectrum of BCLXLCt in presence of 
tBID and lipid vesicles is in support of this observation (Supplementary Fig. 2). Since 
tBID has no tryptophan residues and its contribution to the spectrum is negligible, the 
spectral blue shift obtained for BCLXLCt in the presence of tBID and membranes is 
indicative of a transition of BCLXLCt to a more hydrophobic environment, likely 
accompanied by a conformational change. The effect of tBID is supported by the absence 
of spectral changes for BCLXLCt alone in the presence of LUVs.  
tBID and BCLXLCt cooperate in membrane permeabilization 
tBID has been shown to induce a conformational change to the membrane-bound form of 
the BCLXL homolog BCL2 that is related to the formation of small pores in the lipid 
membrane25. To investigate if BCLXL exhibits a similar behavior, we used the GUV 
approach. We added Alexa543 free dye to the outside solution of the GUV samples 
containing tBIDred and/or BCLXLCtgreen. Membrane permeabilization was monitored 
following the incorporation of the Alexa543 dye into the initially empty interior of the 
giant liposomes. The advantage of this strategy is that protein binding, membrane 
permeabilization and vesicle integrity can be simultaneously accessed. Moreover, 
additional information, for example about heterogeneities in the permeabilization 
process, is obtained in comparison to bulk measurements26, 27. Since membrane 
permeabilization is followed at the level of individual vesicles, the permeabilization 
kinetics of single GUVs can be measured and compared to other vesicles and to the 
kinetics of ensemble sample permeabilization.   
We imaged the effect of tBIDred and/or BCLXLCtgreen on the permeability of GUVs for 
4h at room temperature (Fig. 3a and Supplementary Movie 1). Over that time, most of 
the vesicles were permeabilized in the samples containing both tBIDred and 
BCLXLCtgreen. Single GUV permeabilization was complete in less than 2 min, indicating 
fast kinetics. We analyzed the pore forming activity of the proteins by quantifying the 
permeabilized GUVs. Binding of tBIDred or BCLXLCtgreen individually to the lipid 
membranes caused substantial permeabilization of the vesicles when compared to control 
samples or to non-binding conditions (Fig. 3b). However, the percentage of 
permeabilized liposomes in presence of both tBIDred and BCLXLCtgreen reaches 60% for 
PC:CL (8:2) and 85% for PC:Ni-lipid (99:1). This is nearly two times higher than the 
sum of the activities of the individual proteins for those lipid compositions and supports a 
synergistic effect of tBID and BCLXLCt on their membrane binding and/or 
permeabilizing activities. The increase in the percentage of permeabilized vesicles with 
time and the synergistic effect at several protein concentrations are shown in Figure 3c 
and d, respectively. 
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Binding between tBID and BCLXLCt is enhanced in membranes 
The autocorrelation of the FCS data obtained for tBIDred and BCLXLCtgreen allows 
quantification of their concentrations and diffusion properties. Besides, the cross-
correlation (CC) analysis of tBIDred and BCLXLCtgreen diffusion through the focal 
volume of the microscope provides quantitative information about protein/protein 
binding and can be used for measurements both in solution and in lipid membranes28, 29. 
A scheme of the experimental setup used is depicted in Figure 4a.  
Total tBIDred or BCLXLCtgreen, comprising free protein and protein in the complex give 
rise to the corresponding autocorrelation curves (green and red lines in Fig. 4b,c). But 
only when tBIDred and BCLXLCtgreen interact and diffuse as a complex, the fluorescence 
fluctuations are similar in both channels and contribute to the amplitude of the cross-
correlation curve (blue line in Fig. 4b,c). As a result, the larger the cross-correlation 
amplitude, the higher the concentration of tBID/BCLXLCt complexes is in the sample 
(See Supplementary Methods).  
At concentrations of 100 nM of each protein in PBS, we measured 15 % CC (Fig.4b), 
which indicates the formation of tBID/BCLXLCt complexes in solution. Interestingly, 
we did not observe any cross-correlation for full length BIDred and BCLXLCtgreen at 
concentrations up to 330 nM (Supplementary Fig. 3). These results strongly suggest that 
activation of BID by proteolytic cleavage is necessary to promote binding to BCLXL. 
To overcome the technical difficulties associated with the quantification of complex 
formation in lipid membranes, we used a novel variant of FCS named two-color two-
focus scanning FCS30 (see Methods). tBIDred and BCLXLCtgreen were added to a 
suspension of GUVs composed of PC:CL (8:2) and incubated 2h at room temperature to 
ensure equilibrium conditions before measuring scanning FCS across the membrane 
plane of giant liposomes containing the bound proteins (Fig. 4c). The positive amplitude 
of the cross-correlation curve demonstrated the interaction between tBID and BCLXLCt 
in lipid membranes. Compared to solution, addition of 2 nM tBIDred and 16 nM 
BCLXLCtgreen  (lower than used in solution) to the GUVs suspension provided 40% CC 
(higher than detected in solution), which showed that the interaction between the two 
proteins is enhanced by the presence of lipid membranes. 
The amount of particles forming tBID/BCLXLCt complexes can be calculated from the 
ratio of cross-correlation and autocorrelation amplitudes, allowing the estimation of 
effective dissociation constants. From the FCCS data measured at different protein 
concentrations (Fig. 4d), we obtained a Kd of 20020 nM (12010 molec m-3) (s.d.) for 
complex formation in solution (see Supplementary Fig. 4 and Supplementary 
Methods). This value is in the same order of magnitude as the Kd reported in the 
literature for BH3 peptides8, 31, 32. However, in the presence of lipid membranes, we 
obtained maximum cross-correlation (which is reduced to 45% due to partial protein 
labeling) within the statistical variance at all concentrations measured (Fig. 4e), which 
suggests that the affinity between tBID and BCLXLCt is so high that we were in 
saturation under the conditions tested. This allows us to infer that the Kd in the membrane 
will be lower than 10 molec m-2 and demonstrates a higher affinity between tBID and 
BCLXLCt embedded in lipid membranes when compared with the complex in solution. 
From the respective autocorrelation curves, we calculated that tBID in solution diffused 
at 1439 m2 s-1 (s.d.), while BCLXLCt had a diffusion coefficient of 7810 m2 s-1 
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(s.d.), in agreement with their respective molecular weights (focal volume calibrated with 
Atto65533 and Alexa48834). Under conditions of complex formation with a cross-
correlation of 30%, their average mobility decreased to 533 m2 s-1 (s.d.) for tBID and 
to 586 (s.d.) m2 s-1 for BCLXLCt. As expected, we deduced values from one to two 
orders of magnitude slower from the experiments performed in the presence of lipid 
membranes with two-focus scanning FCS. For the individual proteins, we obtained 
diffusion coefficients of 5.00.3 m2 s-1 and 4.80.7 m2 s-1 (s.d.) for tBID and 
BCLXLCt, respectively. When tBID and BCLXLCt formed complexes in the lipid 
bilayer, these values decreased to 4.40.6 m2 s-1 (s.d.). Since the diffusion coefficient of 
a particle is related to its hydrodynamic radius35, the decrease in mobility observed in the 
presence of tBID/BCLXLCt complexes is in good agreement with the size increase 
associated to complex formation. However, in the case of 2D diffusion in membranes, the 
diffusion coefficient scales with the logarithm of the hydrodynamic radius36, which 
accounts for the weaker effect observed.  
Inhibition of tBID/BCLXLCt complexes in membranes 
The heterodimerization of tBID with BCLXL in solution is believed to happen via 
insertion of the BH3 domain of tBID into the hydrophobic cleft formed by the BH1, BH2 
and BH3 regions of BCLXL. This interaction can be reproduced with peptides derived 
from the BH3 region of BH3-only proteins that bind to the hydrophobic cleft of BCLXL 
and other BCL2 homologs37, 38. As a negative control for our cross-correlation 
experiments and to explore whether the protein-protein interaction surfaces implicated in 
tBID/BCLXL complex formation are similar in solution and in lipid membranes, we 
evaluated the ability of a BH3-derivative peptide (BidBH3) to compete for such 
interactions.  In FCCS experiments in solution, addition of an excess of non-fluorescent 
BidBH3 peptide to the complex tBID/BCLXLCt lead to a decrease in the %CC to values 
close to zero, indicating competitive disruption of the complex (Fig. 5a). Similarly, 
unlabeled, wild-type tBID at ~1µM concentration can also totally displace the 
interactions between tBIDred and BCLXLCtgreen after 3h (Fig. 5b). The kinetics of 
inhibition was similar to that of complex formation (Fig. 5c). Due to solubility problems, 
we could not exceed ~1µM unlabeled tBID in these experiments, which decreased the 
inhibition rate when compared to the peptide. However, when we assayed BidBH3 also at 
~1µM, the extent and rate of inhibition was comparable to unlabeled tBID (data not 
shown). 
In contrast, when we added a mixture of tBIDred, BCLXLCtgreen and an excess of BidBH3 
to a suspension of GUVs, CC values in the membrane were similar to control samples 
without the BH3 peptide (Fig. 5d). This resistance to BidBH3 indicates that even in the 
presence of the peptide, tBID and BCLXLCt bind to the membrane and form a stable 
complex. The inability of BidBH3 to compete for the complex in membranes could be 
related to its low membrane affinity or to the different nature of tBID/BCLXL interactions. 
To distinguish between these possibilities, we used a version of the BidBH3 peptide 
containing a 6-His-tag on the C-terminus (BidBH3His) that can be efficiently targeted to 
membranes containing Ni-lipid. This peptide has been previously shown to potently 
activate BAX39. Interestingly, when we added BidBH3His in a large excess to GUVs 
containing interacting tBID and BCLXLCt, the percentage of complexes remained 
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unaltered. Only when it was added simultaneously with tBID and BCLXLCt to the 
GUVs suspension, the BidBH3His peptide could partially disrupt the complex between 
the proteins (Fig. 5e). A mutant peptide that cannot interact with BCLXL 
(BidBH3HisMUT) did not affect complex formation under the same conditions (Fig. 5e). 
These results indicate that the interactions between tBID and BCLXL in solution and 
within lipid membranes are not equivalent. 
To check if complex formation in the membrane could be totally disrupted, we used 
again unlabeled tBID.  We incubated a suspension of GUVs containing 
tBIDred/BCLXLCtgreen complexes with a molar excess of unlabeled tBID (Fig. 5f, g). The 
cross-correlation amplitude became almost zero (Fig. 5g). These observations indicate 
that unlabeled tBID can bind to BCLXLCtgreen and displace tBIDred from the complex, 
which also means that complex formation in the membrane is reversible.  
Estimation of the number of particles in the membrane focal area showed that the excess 
of unlabeled tBID decreased the number of dual-color fluorescent tBID/BCLXLCt 
particles, but also influenced the membrane binding of tBIDred and BCLXLCtgreen (Fig. 
5h). The number of tBIDred molecules associated to the membrane decreased, indicating 
that tBID binding to lipid bilayers is reversible and only a finite number of binding sites 
is allowed. The increase in the total number of BCLXLCtgreen particles bound to the 
membrane indicates that tBID induces BCLXLCt association to lipid membranes.  
Discussion 
The physiological relevance of the effect of BH3-only proteins on pro-survival BCL2 
members during apoptosis has been described earlier40, although the molecular 
mechanism has not been clarified yet. Our imaging and FCS results show that tBID and 
BCLXLCt enhance each other’s binding to lipid membranes. One of the most relevant 
findings of this study is that tBID promotes BCLXL binding to CL containing vesicles, in 
agreement with recent biochemical experiments41 and providing a molecular basis for the 
translocation of BCLXL to the MOM during apoptosis42. We found that the C-terminal 
transmembrane region of BCLXL is not strictly necessary for membrane binding, though 
it most likely contributes to it. According to our observations, tBID would induce a 
conformational change in BCLXL in the presence of lipid membranes that favors the 
exposure of BCLXL hydrophobic regions important for membrane insertion. These 
probably include the C-terminus but also the central hairpin formed by helices 5 and 643, 
as already reported for BAX and BCL244, 45.  
Moreover, tBID also associated to GUVs containing tethered BCLXL even in the absence 
of CL. This may have physiological implications, since a portion of pro-survival BCL2 
members are located in cellular membranes other than the MOM. It is reasonable to 
postulate that this could be used by cells in order to decrease free tBID molecules that 
could reach the MOM and induce apoptosis46. It could also happen that tBID binding to 
pro-survival BCL2 proteins in the endoplasmic reticulum inactivates their protective 
action and contributes to apoptosis induction47. Moreover, our quantitative analysis 
reveals that tBID binding to CL containing membranes is reversible and probably reaches 
saturation. This suggests that CL acts as a mitochondrial receptor for tBID. However, the 
interaction does not seem stoichiometric one-to-one and other factors, like increased 
membrane tension, may impair further protein insertion into the lipid bilayer. What is 
more interesting is that this implies that tBID membrane binding could be blocked by CL 
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binding competitors. Future work will be required to check if similar behavior can be 
observed in vivo and if it affects apoptosis, hence constituting a new therapeutic target for 
apoptosis regulation. 
Imaging single vesicle permeabilization induced by tBID and BCLXLCt showed that 
membrane integrity is maintained and that the process follows fast kinetics once it starts. 
The cooperative effect observed is in agreement with the high affinity between the two 
proteins in lipid membranes measured by FCCS. This implies that complex formation 
alters membrane permeability, as reported for tBID and BCL248. This activity is difficult 
to reconcile with the antiapoptotic function of BCLXL and BCL2, but in the context of the 
“embedded together” model, pro-survival members behave as defective, dominant-
negative BAX molecules, able to insert and alter the membrane permeability, yet unable 
to oligomerize and release cyt c13, 41. 
In this study, we employed a quantitative approach to examine binding of BID and tBID 
to BCLXLCt in a biochemically well-defined model system. A novel FCCS strategy 
allowed us to evaluate dynamic protein/protein interactions in lipid bilayers and, for the 
first time, we estimated effective dissociation constants for tBID/BCLXLCt complexes 
in solution and in the membrane. Our results show that tBID and BCLXL interact in both 
environments, and importantly, they reveal the dramatic effect of the membrane on their 
effective affinity, which had been underestimated. The molecular details behind this 
effect are related to the reduction of dimensionality in the system from a 3D solution to 
the 2D plane of the membrane, which increases the collision probability, and the 
translocation into an anisotropic, hydrophobic environment, which induces structural 
reorganizations and modifies the thermodynamics of tBID/BCLXLCt interactions. Our 
observations have novel implications for the biological function of tBID and BCLXL, 
since they strongly suggest that the most relevant interaction between these proteins, and 
probably between other homolog proteins of the family, occurs in the membrane, as 
recently reported for BAX and tBID4. Similar membrane-based mechanisms have been 
proposed in other signaling processes, and indeed this could be a general strategy used by 
cells to increase interactions between proteins and to modulate downstream cellular 
responses49-51.  The strong effect of the membrane on tBID/BCLXL complex formation 
begs other questions, like the role of lipids in the function of the BCL2 proteins, the 
structures of these proteins in the membrane-bound state or the nature of the interaction 
surfaces in the lipidic environment. 
The absence of interactions between full length BID and BCLXLCt under the conditions 
investigated links the activation of BID and its role as an apoptosis inducer to the 
promotion of its interactions with BCLXL and probably other members of the BCL2 
family.  
A BH3-derived Bid peptide (BidBH3) induced dissociation of the tBID/BCLXLCt 
complex in solution, but not when the complex was stabilized in lipid membranes. Even 
when BidBH3 efficiently shifts the equilibrium in solution, tBID and BCLXLCt 
translocated to the lipid bilayer and formed complexes. To ensure accessibility of the 
peptide to the membrane, we used a His-tagged version (BidBH3His) which can be 
tethered to membranes containing Ni-lipid and has been shown to efficiently activate 
BAX52. However, membrane targeted BidBH3His could not disrupt previously formed 
tBID/BCLXLCt complexes within membranes and was only able to block complex 
formation partially when added simultaneously with tBID and BCLXLCt, this is, prior to 
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complex formation. These findings are extremely interesting because they indicate the 
existence of two populations of tBID and BCLXLCt with different susceptibility to the 
BH3 peptide in membranes. Based on the different membrane-bound states proposed for 
BCL2 proteins53, it is tempting to speculate that BidBH3His could bind to membrane-
associated BCLXLCt but not to the membrane inserted form, which in turn is still able to 
interact with tBID. This could be explained in terms of the low hydrophobicity of 
BidBH3His that would not be able to insert into the lipid bilayer and displace the more 
hydrophobic tBID from the complex with BCLXL. But also, the existence of alternative 
binding sites for the membrane inserted proteins that further stabilize the complex cannot 
be ruled out. The differences observed with BAX activation by BidBH3His could be 
based on the induction of BAX association with the membrane by the peptide. In such a 
situation, BAX would then insert into the membrane and form pores, for which the 
peptide is not necessary anymore. 
Given the importance of BCL2 targeting in cancer therapy, these findings have important 
consequences for the design of inhibitors of BCL2 pro-survival proteins54. Membrane 
inserted tBID/BCLXL appear as an additional drug target that cannot be inhibited with 
BH3 mimetics and related molecules, but probably with more lipophilic compounds. 
Indeed, the small molecule ABT-737 and PUMA induced apoptosis by releasing tBID 
from complexes with prosurvival BCL2 members within mitochondria, which was 
associated with a “direct activator:prosurvival BCL2 protein:sensitizer/derepressor” 
network55. Also, the proapoptotic effect of the small molecule obatoclax has been linked 
to its ability to block MCL1 in the membrane56. Importantly, the experimental approach 
shown here constitutes a powerful method to investigate the molecular mechanism of 
BCLXL inhibitors quantitatively.  
The contribution of the membrane to the modulation of the interactions between BCL2 
proteins showed here support the “embedded together” hypothesis. It constitutes an 
additional regulatory step of apoptosis and reveals a more complex scenario with multiple 
parallel equilibriums that affect the final event of MOM permeabilization. This is 
consistent with our observations that BidBH3His cannot dissociate totally the 
tBID/BCLXLCt complex stabilized in lipid membranes, indicating that the protein-
protein interactions in solution and in the membrane are not equivalent. Understanding 
the molecular mechanisms of the BCL2 proteins involves detailed knowledge of their 
interaction networks. Therefore, introduction of BAX and derepressor/sensitizer BH3-
only proteins in the system, and quantification of their relative affinities in solution and in 
lipid membranes will help to identify which interactions within the family are favored 
and thus, crucial for MOM permeabilization regulation. 
Altogether, the data reported here support a new model in which BID cleavage acts as a 
switch that allows its interaction with BCLXL and probably other multi-domain BCL2 
proteins (Fig. 6). The active fragment tBID is then capable of binding to BCLXL in 
solution and induce its translocation into the MOM, which is accompanied by 
conformational changes and alteration of the membrane permeability. tBID also binds 
BCLXL in the membrane, where their effective affinity is greatly enhanced so that BCLXL 
can inhibit tBID more efficiently. As a consequence, neutralization of tBID action by 
BCLXL happens mainly within the membrane. Such scenario also implies that tBID 
promotes BCLXL inhibitory activity, which may constitute a control mechanism to avoid 
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unwanted MOM permeabilization while ensuring rapid induction of apoptosis once tBID 
is displaced by derepressor BH3-only proteins. 
In summary, our findings show the active role of the membrane in modulating the 
interactions between tBID and BCLXL. This has important consequences for the current 
understanding of apoptosis regulation, as we have introduced in a new model for BCLXL 
inhibition of tBID. We found unanticipated strong interactions between tBID and BCLXL 
in lipid membranes, as compared to the interactions in solution. This was possible thanks 
to unprecedented quantitative binding studies with full-length BCL2 proteins in both 
environments. Our results link the cleavage of BID to a change in its affinity for BCLXL 
that allows complex formation. The findings that tBID and BCLXL induce each other’s 
binding to membranes and that they cooperate to induce membrane permeabilization are 
in good agreement with the formation of a stable complex within the membrane, where, 
as a consequence, the main inhibition of tBID by BCLXL takes place. Importantly, the 
distinct susceptibility to BH3 peptides in solution and tethered to membranes 
demonstrates the existence of different tBID/BCLXL complex conformations in both 
environments. Our novel experimental approach offers new perspectives on the 
molecular mechanisms of interactions at interfaces. The quantitative analysis based on 
FCS constitutes a promising strategy for a better understanding of the regulation of BCL2 
proteins and for the investigation of protein/protein interactions within membranes in 
general, an issue that has proven extremely challenging so far. 
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FIGURE LEGENDS 
 
Figure 1 Fluorescently labeled tBID and BCLXLCt retain their apoptotic activity. (a) 
and (b) Structures of soluble BID and BCLXLCt respectively, obtained from pdb models 
(PBD 2BID57 and PDB 1LXL58). Mutation of Cys to Ser is shown in yellow, mutation of 
Ser to Cys is shown in red, and the cleavage site of BID by caspase 8 is depicted in green. 
The stars indicate the single Cys sites at which the fluorophores are attached. (c) 
Cytochrome c (cyt c) release from mitochondria at different concentrations of unlabeled 
tBID (lanes 2 and 3) or tBIDred (lanes 4 and 5). Released cytc is detected in the 
supernatant fraction, while cyt c associated to mitochondria remains in the pellet fraction. 
(d) BCLXLCtgreen blocks cyt c release from mitochondria induced by tBID in a 
concentration dependent manner.  
 
Figure 2 Binding of tBIDred and BCLXLCtgreen to giant unilamellar vesicles. Pictures on 
the right and left panels depict the same sample imaged on different channels of the 
microscope. On the left, giant unilamellar vesicles (GUVs) are labeled with 0.05% of a 
hydrophobic dye, DiO shown in green, or DiD shown in red. The panels on the right 
show protein binding to the same GUVs. tBIDred (red) did not associate to GUVs 
composed of PC:PG (8:2) (a-b), but showed binding to GUVs containing cardiolipin 
(PC:CL, 8:2, panels c-d). BCLXLCt tethered to GUVs via DOGS-NTA-Ni (PC:DOGS-
NTA-Ni, 99:1) promoted tBIDred binding to GUVs, even in the absence of cardiolipin (e-
f). As a control, full length BIDgreen (green) did not bind to PC:CL (8:2) vesicles (g-h). In 
the case of BCLXLCtgreen (green), it did not associate to anionic membranes (PC:CL, 
8:2) at pH 7 (i-j), but bound at pH5 (k-l). Panels (m-n) show BCLXLCtgreen tethering to 
membranes containing DOGS-NTA-Ni (PC:DOGS-NTA-Ni, 99:1). (o-p) tBID induced 
BCLXLCtgreen binding to membranes containing cardiolipin (PC:CL, 8:2). Scale bar 15 
m. 
 
Figure 3 tBIDred and BCLXLCtgreen cooperate on membrane permeabilization. (a) 
Kinetics of GUV permeabilization in the presence of tBIDred and BCLXLCtgreen, 
monitored by the internalization of free Alexa543 externally added. Permeabilized 
vesicles pointed with white arrows. Time in minutes. Scale bar 10 m. (b) Percentage of 
permeabilized vesicles after addition of 16 nM BCLXLCtgreen and/or 9 nM tBIDred. Error 
bars are s.d. (c) Increase of the percentage of permeabilized vesicles with time after 
addition of 32 nM BCLXLCtgreen and/or 18 nM tBIDred. The white circles correspond to a 
control experiment without proteins added. (d) Percentage of vesicle permeabilization at 
several concentrations of BCLXLCtgreen and/or tBIDred. In (c) and (d) GUVs are 
composed of PC:CL (8:2). Error bars correspond to s.d. 
 
Figure 4 Measurement of tBID/BCLXLCt interactions by fluorescence cross-correlation 
spectroscopy. (a) The optical setup is based on an inverted laser scanning microscope. 
The laser light from 488 and 633 nm lines is focused onto the sample. Diffusion and 
binding of labeled proteins in solution are measured with fluorescence correlation 
spectroscopy (FCS) using a fixed focal volume. For measurements in the membrane, 
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scanning FCS is used and the focal volume is scanned perpendicularly through the 
membrane plane. The photons emitted are spectrally split by a dichroic mirror and 
detected with avalanche photo diodes coupled to an online autocorrelator. Data are 
analyzed with a computer using custom software. (b) Auto- and cross-correlation (CC) 
analysis of measurements in solution. The fitted autocorrelation curves of tBIDred and 
BCLXLCtgreen are shown in orange and green, respectively. The amplitude of the fitted 
CC curve (blue) indicates formation of tBID/BCLXLCt complexes. (c) Auto- and CC 
global analysis of two-focus scanning FCCS measurements in the membrane of GUVs. 
The orange and green lines correspond to the fitted autocorrelation curves of tBIDred and 
BCLXLCtgreen, respectively. The light blue and yellow lines show the two-focus analysis 
for tBIDred and BCLXLCtgreen, respectively. Eq.(8) (see Supplementary Methods) was 
used for the global fitting. Interactions between tBID and BCLXLCt in the membrane are 
demonstrated by the amplitude of the CC curve (dark blue line). GUVs composed of 
PC:CL (8:2). Thin black lines depict raw data. (d) and (e) Quantification of 
tBID/BCLXLCt complexes, expressed as %CC, as a function of tBID concentration in 
solution (d) and in the membrane (e). 
 
Figure 5 Inhibition of tBID/BCLXLCt interactions in solution and in the membrane. (a) 
tBID/BCLXLCt complex in solution can be disrupted by addition of BidBH3, as shown 
by the neutralization of the CC curve (solid blue) after incubation with 1,7 M of 
BidBH3 (dashed blue). Concentrations of tBIDred and BCLXLCtgreen were 220 nM and 
160 nM, respectively. (b) Similarly, unlabeled tBID (1 µM) can also disrupt the 
complex between tBIDred and BCLXLCtgreen after 3h incubation. Concentrations of 
tBIDred and BCLXLCtgreen were 200 nM and 180 nM, respectively. (c) Time course of 
the experiments in (a), (), and (b), (). %CC, related to complex concentration, was 
calculated with respect to tBIDred. Error bars are averaged absolute errors from the FCCS 
fittings. (d) Addition of BidBH3 excess does not inhibit tBID/BCLXLCt interactions in 
lipid membranes (PC:CL, 8:2). The amplitude of the CC curves (blue) is similar in 
absence (solid line) and presence (dashed line) of 400 pmol BidBH3. (e) The membrane 
targeted peptide BidBH3His (~1.13 µmol) can partially disrupt the tBID/BCLXLCt 
complex in the membrane if added simultaneously (0’) with the proteins, but not after 
they have formed the complex in the membrane (2 h). GUVs composed PC:CL:Ni-lipid, 
75:20:5. Error bars are s.d. (f) and (g) tBIDred/BCLXLCtgreen complex in GUVs (PC:CL, 
8:2) can be totally disrupted by unlabeled tBID. The amplitude of the CC curve (blue) in 
(f) decreases and after addition of 400 pmol unlabeled tBID to GUVs (g). GUVs 
samples contain 9 pmol BCLXLCtgreen and 3 pmol tBIDred. In all graphs, green and 
orange lines correspond to the autocorrelation of BCLXLCtgreen and tBIDred, respectively. 
Raw data shown in black. Eq.(8) (see Supplementary Methods) was used for the global 
fitting. (h) Number of particles in the membrane focal area before and after addition of 
unlabeled tBID. Excess of unlabeled tBID increases total BCLXLCtgreen bound to the 
membrane, but decreases total tBIDred and tBID/BCLXLCt complex. Error bars are s.d. 
 
Figure 6 Proposed model for the interactions between tBID and BCLXL. (a) Initially, 
BCLXL and BID do not interact. (b) Upon cleavage during apoptosis, tBID is able to bind 
BCLXL. tBID and BCLXL promote each other’s binding to the membrane, where they 
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have a higher affinity for each other (indicated by the thickness of the two-headed 
arrows). (c) As a consequence, BCLXL inhibition of tBID happens mainly at the 
membrane. 
Methods 
Protein preparation. We prepared fluorescently labeled human tBID as described59, 
from BID cDNA in pET15b with a single Cys at position 64 in the tBID fragment and 
labeled it with Alexa647 maleimide (Invitrogen). We purified full length BID with the 
same protocol as tBID, but from a cDNA with C15S and C28S mutations, and labeled it 
with Bodipy or Alexa647 maleimide. 
We introduced mutations S2C and C151S in human BCLXL1-209 (BCLXLCt) in a 
modified pET15b vector. We overexpressed the protein in E. coli. For purification, we 
used in a His-trap HP column (Amersham Biosciences) with an imidazole gradient in 50 
mM Na2HPO4, 300 mM NaCl 1 mM DTT, pH 7. Then, we dialyzed the protein against 
50 mM Na2HPO4, 300 mM NaCl, 1 mM DTT, pH 7 and labeled it with Alexa488 
maleimide. 
Release of cytochrome c from isolated mitochondria. We isolated mouse liver 
mitochondria as described60 (for details, see Supplementary Methods). We performed 
experiments of cyt c release with 60 g of isolated mitochondria in AT buffer 
supplemented with 5 mM succinate, 2 mM ATP, 10 M phosphocreatine and 10 g ml–1 
creatine kinase. We incubated the indicated proteins for 1 h at 37°C in a volume of 30 
L. We centrifuged the samples at 5,500 g for 10 min at 4°C. We checked the presence 
of cyt c in the pellets and supernatants by western blot with a cyt c antibody (BD 
Biosciences). 
Preparation of giant unilamellar vesicles. All lipids were from Avanti Polar 
Lipids. We prepared GUVs by the electroformation method. We spread 5 L of lipid 
mixture at 1 mg ml-1 in chloroform on two Pt wire electrodes. We immersed the lipid 
films in a chamber containing 300 mM sucrose solution and connected the Pt wires to a 
power generator. We performed electroformation at 2.3 V and 10 Hz for 1h at room 
temperature. We released the GUVs from the electrodes by changing the frequency to 2 
Hz for 30 min. 
Protein binding and membrane permeabilization assays. We sedimented 50 L 
of GUVs electroformed in 300 mM sucrose in 500 L PBS containing the corresponding 
proteins. We added 16 nM of BCLXLCt green, 9 nM of tBIDred and/or 290 nM unlabeled 
tBID, as indicated. After 2h incubation r.t., we measured protein binding to the GUVs 
by confocal microscopy. We used an LSM 510 Meta microscope (Zeiss) with a 40x 1.2 
NA C-Apochromat water objective (Zeiss) in the multi-track modus. We used 
UV/488/543/633 and 545 nm filters as main and secondary dichroics. The green channel 
consisted of an Ar laser with excitation wavelength at 488 nm and a 505–530 nm band 
pass filter, while we configured the red channel with a 633 nm excitation laser and a 650 
nm long pass filter.  
For the GUVs permeabilization experiments, we added 5 L of 50 M Alexa 543 free 
dye to GUVs samples containing 16 nM BCLXLCt green and/or 9 nM tBIDred and 
measured dye entrance into the GUVs with time. We imaged it in a different track with a 
543 nm excitation laser and a 560–615 nm band pass filter. After 4 h incubation at r.t., we 
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acquired images over a large area of the sample and counted the permeabilized and non-
permeabilized GUVs. We repeated all experiments at least three times and measured 
several hundreds of vesicles per experiment. 
Fluorescence correlation spectroscopy. We performed FCS and FCCS 
measurements at 22°C on an laser scanning microscope (LSM) Meta 510 system (Carl 
Zeiss, Jena, Germany) using a 40x NA 1.2 UV-VIS-IR C Apochromat water-immersion 
objective, the 488 nm line of an Argon-ion laser (25 µW), the 633 nm HeNe laser (15 
µW) and a home-built detection unit at the fiber output channel. We used a dichroic 
mirror and band-pass filters (D555, HQ520/40 and HQ700/75, AHF Analyse Technik, 
Tuebingen, Germany) behind a collimating achromat to split the emission for the dual 
color detection and to reject residual laser and background light. We then used achromats 
(LINOS Photonics, Goettingen, Germany) to image the internal pinhole onto the 
apertures of the fibers connected to the avalanche photodiodes (APD, PerkinElmer, 
Boston, MA). We recorded the photon arrival times in the photon mode of the hardware 
correlator Flex 02-01D (Correlator.com, Bridgewater, NJ). 
For scanning FCS30, we repeatedly scanned the detection volume perpendicularly through 
the equator of a GUV. We controlled its movement directly with the Zeiss LSM 
operation software. We used the frame mode with Nx2 pixels to scan the two parallel 
lines. We measured their distance d by repeatedly scanning over a film of dried 
fluorophores and measuring the distance between the bleached traces in a high resolution 
LSM-image.  
We performed data analysis with software written in MATLAB (MathWorks, Natick, 
MA). For scanning FCS, we binned the photon stream in bins of 2 µs and arranged it as a 
matrix such that every row corresponded to one line scan. We corrected for movements 
of the membrane by calculating the position of the maximum of a running average over 
several hundred line scans and shifting it to the same column. We fitted an average over 
all rows with a Gaussian and we added only the elements of each row between –2.5 and 
2.5 to construct the intensity trace. We computed the auto- and cross-correlation curves 
of the resulting intensity traces with a multiple tau correlation algorithm and fitted them 
with a nonlinear least squares fitting algorithm. In all FCS data processing, we excluded 
from further analysis irregular curves resulting from major instabilities and identified by 
distortions of the curves and a systematic change in the intensity trace. We fitted the 
resulting auto- and cross-correlation functions to analytical models as described in 
Supplementary Methods. We checked that the FCS analysis was not affected by dye 
quenching due to complex formation or oligomerization by FIDA in solution and by 
analyzing the counts per molecule of the fluorophores in membranes (See 
Supplementary Methods and Supplementary Fig. 5). For details on the calculation of 
the Kd values from the FCS and FCCS data see Supplementary Methods. 
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